Kymera Therapeutics

KT-413 Clin1 oncology; KT-333 Clin1 multiple cancers; KT-253 Clin0 multiple cancers; 5 undisclosed programs RD autoimmune & fibrotic diseases, immune-inflammatory diseases, oncology

Kymera Therapeutics is developing novel protein degrader therapeutics to treat disease. Cells possess various ways to selectively degrade proteins. Kymera is harnessing these natural processes to selectively degrade disease causing proteins to remove them from the body. To identify effective methods, Kymera is using their proprietary targeted protein degradation platform, Pegasus, which enables the design of highly selective, heterobifunctional small molecule protein degraders. Pegasus works by combining E3 Ligase whole-body expression levels and binders with quantitative system pharmacology. Kymera’s investigational drugs are in development to treat a broad range of immune-inflammatory diseases, hematologic malignancies and solid tumors.